LU
LUCD.US Lucid Diagnostics Inc
- Market cap
- USD 87.4M
- P/E
- -
- P/B
- 14.85x
- ROE
- -725.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is LUCD.US undervalued?
Graham numberThe Graham number of Lucid Diagnostics Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Lucid Diagnostics Inc fundamental analysis
No fundamental analysis for Lucid Diagnostics Inc yet.
Lucid Diagnostics Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of pr…
Full company profileLucid Diagnostics Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Lucid Diagnostics Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | 0.00 | 0.00 | 500K | 377K | 2.43M | 4.35M | 4.71M | 5.24M |
| Gross Profit | - | - | 0.00 | -85.0K | -3.24M | -6.05M | -3.92M | -2.84M | -1.02M |
| Operating Income | -1.13M | -4.42M | -8.28M | -27.4M | -56.2M | -48.5M | -46.1M | -49.6M | -49.6M |
| EBITDA | 563K | -4.42M | -8.28M | -27.4M | -54.2M | -49.8M | -44.3M | -57.1M | -42.1M |
| Net Income | -1.13M | -4.42M | -8.28M | -28.1M | -56.2M | -52.7M | -45.5M | -58.0M | -43.0M |
| EPS | -0.03 | -0.12 | -0.22 | -0.78 | -1.55 | -1.26 | -0.90 | -0.57 | -0.23 |
| Balance Sheet | |||||||||
| Total Assets | 17.8K | 1.03M | 2.20M | 59.0M | 32.5M | 27.3M | 30.7M | 40.4M | 27.9M |
| Total Liabilities | 1.08M | 6.34M | 15.7M | 4.26M | 9.46M | 29.6M | 25.3M | 29.5M | 21.9M |
| Shareholders' Equity | -1.06M | -5.31M | -13.5M | 54.7M | 23.0M | -2.31M | 5.39M | 10.9M | 5.93M |
| Cash & Short-term Investments | 17.8K | 156K | 111K | 53.7M | 22.5M | 18.9M | 22.4M | 34.7M | 18.0M |
| Total Debt | - | - | - | - | 2.00M | 15.3M | 21.3M | 25.8M | 18.5M |
| Cash Flow | |||||||||
| Operating Cash Flow | -171K | -2.36M | -5.63M | -17.7M | -29.7M | -32.8M | -44.1M | -46.5M | -51.9M |
| Capital Expenditure | 862K | 4.00 | 862K | 862K | 908K | 221K | 646K | 197K | 337K |
| Free Cash Flow | -114K | -2.36M | -5.63M | -18.5M | -30.6M | -33.0M | -44.8M | -46.7M | -52.3M |
| Ratios | |||||||||
| ROE | - | - | - | -51.3% | -243.7% | - | -844.5% | -530.4% | -725.4% |
| ROA | -6,325.8% | -427.6% | -377.2% | -47.6% | -172.8% | -193.1% | -148.2% | -143.4% | -154.5% |
| Net Profit Margin | - | - | - | -5,615.6% | -14,899.5% | -2,169.1% | -1,047.6% | -1,232.7% | -820.6% |
| Debt to Equity | - | - | - | - | 0.09x | - | 3.94x | 2.36x | 3.12x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Lucid Diagnostics Inc dividends
Lucid Diagnostics Inc has not paid dividends in the last 8 fiscal years.
Who owns Lucid Diagnostics Inc
- Insiders 24.99%
- Institutions 28.89%
- Public & others 46.12%
- Shares outstanding 195M
- Free float 145M
Top funds holding LUCD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 4.55M | 2.38% | 0.00% | Sep 2026 |
| abrdn Healthcare Opportunities | 4.42M | 2.31% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 3.49M | 1.83% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 1.58M | 0.83% | 0.00% | Aug 2026 |
| iShares Russell 2000 Growth ETF | 1.41M | 0.74% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 895K | 0.47% | +5.06% | Sep 2026 |
| Fidelity Extended Market Index | 656K | 0.34% | -16.52% | Sep 2026 |
| iShares Micro-Cap ETF | 466K | 0.24% | 0.00% | Oct 2026 |
| Schwab Small Cap Index | 407K | 0.21% | +12.16% | Sep 2026 |
| Fidelity Total Market Index | 295K | 0.15% | -0.05% | Sep 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 278K | 0.15% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 230K | 0.12% | 0.00% | Sep 2026 |
| Nuveen Small Cap Blend Idx R6 | 195K | 0.10% | 0.00% | Sep 2026 |
| Bridge Builder Small Cap Fund | 185K | 0.10% | +885.35% | Oct 2026 |
| Vanguard Russell 2000 Growth ETF | 162K | 0.08% | +0.01% | Sep 2026 |
| EQ/2000 Managed Volatility IB | 155K | 0.08% | 0.00% | Sep 2026 |
| Fidelity Small Cap Growth Index | 153K | 0.08% | +4.82% | Aug 2026 |
Top institutions holding LUCD.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Alyeska Investment Group, L.P. | 8.86M | 4.64% | 0.00% | Jun 2026 |
| BlackRock Inc | 8.37M | 4.38% | +80.52% | Jun 2026 |
| Vanguard Capital Management, LLC | 6.56M | 3.43% | +57.80% | Jun 2026 |
| Aberdeen Group PLC | 4.42M | 2.31% | +15.61% | Sep 2026 |
| Masters Capital Management LLC | 4.00M | 2.09% | 0.00% | Jun 2026 |
| Geode Capital Management, LLC | 3.79M | 1.98% | +68.79% | Jun 2026 |
| State Street Corp | 2.44M | 1.28% | +56.78% | Jun 2026 |
| First Manhattan Co. LLC | 2.19M | 1.15% | +576.63% | Jun 2026 |
| Wells Fargo & Co | 2.07M | 1.08% | +62.20% | Jun 2026 |
| Northern Trust Corp | 1.22M | 0.64% | +81.91% | Jun 2026 |
| Perkins Capital Management Inc | 1.13M | 0.59% | -0.09% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 1.07M | 0.56% | +71.29% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.02M | 0.54% | +93.33% | Jun 2026 |
| UBS Group AG | 845K | 0.44% | +89.75% | Jun 2026 |
| AQR Capital Management LLC | 723K | 0.38% | +208.05% | Jun 2026 |
| Lido Advisors, LLC | 447K | 0.23% | +16.62% | Jun 2026 |
| Charles Schwab Investment Management Inc | 325K | 0.17% | +64.78% | Jun 2026 |
| XML Financial, LLC | 323K | 0.17% | 0.00% | Sep 2026 |
| Bank of New York Mellon Corp | 302K | 0.16% | +46.24% | Jun 2026 |
| Bank of Montreal | 290K | 0.15% | +1.65% | Jun 2026 |
Lucid Diagnostics Inc company profile
- Company name
- Lucid Diagnostics Inc
- Ticker
- LUCD.US
- Exchange
- USA Stocks
- Listed since
- Oct 14, 2021
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 82
- Fiscal year end
- December
- Address
- 360 Madison Avenue, New York, NY, United States, 10017
- Phone
- 917 813 1828
- Website
- luciddx.com
About Lucid Diagnostics Inc
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company in the United States. It focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma. The company's flagship product, the EsoGuard Esophageal DNA Test performed on samples collected with the EsoCheck Esophageal Cell collection device, a testing tool with the goal of preventing EAC deaths through early detection of esophageal precancer in at-risk GERD patients. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. operates as a subsidiary of PAVmed Inc.
Lucid Diagnostics Inc management
10- Dr. Lishan Aklog M.D.Chairman & CEO · born 1966
- Mr. Shaun M. O'Neill M.B.A.President & COO · born 1982
- Mr. Dennis M. McGrath CPAChief Financial Officer · born 1957
- Mr. Michael Adam GordonGeneral Counsel & Secretary · born 1975
- Dr. Sanford D. Markowitz M.D., Ph.D.Co-Founder & Strategic Advisor
- Dr. Joseph Willis M.D.Co-founder & Strategic Advisor
- Dr. Amitabh Chak M.D.Co-Founder & Strategic Advisor
- Helen Moinova Ph.D.Co-Founder & Strategic Advisor
- Dr. Brian J. deGuzman M.D.Chief Technology & Compliance Officer · born 1965
- Dr. Suman M. Verma M.D., Ph.D.Senior VP & Chief Scientific Officer